{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:24:14Z","timestamp":1791462254759,"version":"4.3.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cmi.2025.06.015","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T15:45:22Z","timestamp":1750261522000},"page":"1458-1466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Challenges and strategies in the treatment of periprosthetic joint infection caused by multidrug-resistant Gram-negative bacteria: a narrative review"],"prefix":"10.1016","volume":"31","author":[{"given":"Joan","family":"G\u00f3mez-Junyent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Lora-Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Sorl\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.06.015_bib1","doi-asserted-by":"crossref","first-page":"732.e1","DOI":"10.1016\/j.cmi.2016.05.004","article-title":"Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study","volume":"22","author":"Benito","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.06.015_bib2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1469-0691.2010.03361.x","article-title":"Gram-negative prosthetic joint infection treated with debridement, prosthesis retention and antibiotic regimens including a fluoroquinolone","volume":"17","author":"Aboltins","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.06.015_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMra2203477","article-title":"Periprosthetic joint infection","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.015_bib4","doi-asserted-by":"crossref","first-page":"O911","DOI":"10.1111\/1469-0691.12649","article-title":"Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study","volume":"20","author":"Rodr\u00edguez-Pardo","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.06.015_bib5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1128\/AAC.35.4.741","article-title":"Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections","volume":"35","author":"Widmer","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib6","first-page":"187","article-title":"Epidemiological and clinical features of prosthetic joint infections caused by gram-negative bacteria","volume":"23","author":"Fantoni","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cmi.2025.06.015_bib7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijantimicag.2018.10.018","article-title":"Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: role of surgery and impact of colistin administration","volume":"53","author":"Papadopoulos","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.06.015_bib8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.015_bib9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10096-010-0950-y","article-title":"Antibiotic resistance in orthopaedic surgery: acute knee prosthetic joint infections due to extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae","volume":"29","author":"Mart\u00ednez-Pastor","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.015_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijantimicag.2012.09.016","article-title":"Difficult-to-treat Gram-negative bone and joint infections: efficacy and safety of prolonged intravenous colistin","volume":"41","author":"Valour","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.06.015_bib11","first-page":"3357","article-title":"Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus \u03b2-lactams","volume":"70","author":"Ribera","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib12","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/jac\/dkw202","article-title":"Gram-negative prosthetic joint infections managed according to a multidisciplinary standardized approach: risk factors for failure and outcome with and without fluoroquinolones","volume":"71","author":"Grossi","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s15010-018-1116-6","article-title":"Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use","volume":"46","author":"Ribera","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2025.06.015_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/jcm8020220","article-title":"Orthopedic implant-associated infection by multidrug resistant enterobacteriaceae","volume":"8","author":"Pfang","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.cmi.2025.06.015_bib15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.medmal.2018.12.002","article-title":"Characteristics of Enterobacter cloacae prosthetic joint infections","volume":"49","author":"Bouige","year":"2019","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.cmi.2025.06.015_bib16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s13318-020-00625-5","article-title":"Efficacy and therapeutic drug monitoring of continuous \u03b2-lactam infusion for osteoarticular infections caused by fluoroquinolone-resistant Pseudomonas aeruginosa: A prospective cohort study","volume":"45","author":"G\u00f3mez-Junyent","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cmi.2025.06.015_bib17","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/antibiotics10030340","article-title":"Outcomes and risk factors in prosthetic joint infections by multidrug-resistant Gram-negative bacteria: A retrospective cohort study","volume":"10","author":"da Silva","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.06.015_bib18","article-title":"Pseudomonas aeruginosa prosthetic joint-infection outcomes: Prospective, observational study on 43 patients","volume":"9","author":"Pri\u00e9","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.cmi.2025.06.015_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s15010-024-02379-7","article-title":"Efficacy and safety of colistin plus beta-lactams for bone and joint infection caused by fluoroquinolone-resistant gram-negative bacilli: A prospective multicenter study","volume":"53","author":"Manche\u00f1o-Losa","year":"2025","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2025.06.015_bib20","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMra040181","article-title":"Prosthetic-joint infections","volume":"351","author":"Zimmerli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.015_bib21","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1016\/j.arth.2018.09.026","article-title":"Hip and knee section, treatment, one stage exchange: Proceedings of International Consensus on Orthopedic Infections","volume":"34","author":"Bialecki","year":"2019","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.cmi.2025.06.015_bib22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jinf.2018.08.017","article-title":"Debridement, antibiotics and implant retention for periprosthetic joint infections: A systematic review and meta-analysis of treatment outcomes","volume":"77","author":"Kunutsor","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2025.06.015_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41598-018-36313-3","article-title":"One- and two-stage surgical revision of infected shoulder prostheses following arthroplasty surgery: A systematic review and meta-analysis","volume":"9","author":"Kunutsor","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2025.06.015_bib24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/jcm8050673","article-title":"The different microbial etiology of prosthetic joint infections according to route of acquisition and time after prosthesis implantation, including the role of multidrug-resistant organisms","volume":"8","author":"Benito","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.cmi.2025.06.015_bib25","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.arth.2019.01.066","article-title":"Failed debridement and implant retention does not compromise the success of subsequent staged revision in infected total knee arthroplasty","volume":"34","author":"Kim","year":"2019","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.cmi.2025.06.015_bib26","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.arth.2018.02.087","article-title":"Does prior failed debridement compromise the outcome of subsequent two-stage revision done for periprosthetic joint infection following total knee arthroplasty?","volume":"33","author":"Rajgopal","year":"2018","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.cmi.2025.06.015_bib27","first-page":"17168","article-title":"Multidrug resistant bacteria: An independent prognostic variable for failure in lower limb joint arthoplasty?","author":"Hammad","year":"2020","journal-title":"J Orthop"},{"key":"10.1016\/j.cmi.2025.06.015_bib28","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2019.07.009","article-title":"Colistin-containing cement spacer for treatment of experimental carbapenemase-producing Klebsiella pneumoniae prosthetic joint infection","volume":"54","author":"Gatin","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.06.015_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.arth.2006.05.006","article-title":"Management of a multidrug-resistant Pseudomonas aeruginosa infected total knee arthroplasty using colistin. A case report and review of the literature","volume":"22","author":"Papagelopoulos","year":"2007","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.cmi.2025.06.015_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40001-020-00428-z","article-title":"The stability of carbapenems before and after admixture to PMMA-cement used for replacement surgery caused by Gram-negative bacteria","volume":"25","author":"Schmid","year":"2020","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.cmi.2025.06.015_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CORR.0000000000002364","article-title":"Meropenem-loaded cement is effective in preventing Gram-negative osteomyelitis in an animal model","volume":"481","author":"Wei","year":"2023","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.cmi.2025.06.015_bib32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cmi.2023.12.008","article-title":"In vitro susceptibility to delafloxacin of Pseudomonas aeruginosa with resistance to other quinolones (ciprofloxacin and levofloxacin)","volume":"30","author":"Jord\u00e1n-Chaves","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.06.015_bib33","doi-asserted-by":"crossref","first-page":"ofad319","DOI":"10.1093\/ofid\/ofad319","article-title":"Clinical risk scores to predict nonsusceptibility to trimethoprim-sulfamethoxazole, fluoroquinolone, nitrofurantoin, and third-generation cephalosporin among adult outpatient episodes of complicated urinary tract infection","volume":"10","author":"Lodise","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.015_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/1471-2334-14-393","article-title":"Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: A longitudinal epidemiological study from 2002\u20132011","volume":"14","author":"Wong","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.015_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01232-24","article-title":"Targeted antimicrobial regimens for Gram-negative prosthetic joint infections: A prospective multicenter study","volume":"68","author":"Hanssen","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib36","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1093\/jac\/dkae328","article-title":"Efficacy and safety of co-trimoxazole in device-related bone and joint infections: A CRIOGO multicentre case-control study","volume":"79","author":"Lecomte","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib37","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jac\/41.5.571","article-title":"Biofilms and beta-lactam activity","volume":"41","author":"Gilbert","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","article-title":"Penetration of antibacterials into bone: Pharmacokinetic, pharmacodynamic and bioanalytical considerations","volume":"48","author":"Landersdorfer","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2025.06.015_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106856","article-title":"Efficacy of meropenem extended infusion vs. intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm","volume":"62","author":"Benavent","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.06.015_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106246","article-title":"In vitro pharmacokinetics\/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm","volume":"57","author":"G\u00f3mez-Junyent","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.06.015_bib41","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1128\/AAC.06486-11","article-title":"In vivo pharmacokinetics\/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection","volume":"56","author":"Hengzhuang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib42","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/1469-0691.12651","article-title":"Antimicrobial susceptibility testing in biofilm-growing bacteria","volume":"20","author":"Maci\u00e0","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.06.015_bib43","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ijantimicag.2019.01.010","article-title":"Efficacy of ceftolozane\/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model","volume":"53","author":"Gomez-Junyent","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.06.015_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01230-19","article-title":"Comparative antibiofilm efficacy of meropenem alone and in combination with colistin in an in vitro pharmacodynamic model by extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae","volume":"63","author":"Ribera","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jinf.2012.09.004","article-title":"Prolonged subcutaneous high dose (1 g bid) of Ertapenem as salvage therapy in patients with difficult-to-treat bone and joint infection","volume":"65","author":"Ferry","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2025.06.015_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2958.2008.06152.x","article-title":"Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes","volume":"68","author":"Pamp","year":"2008","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cmi.2025.06.015_bib47","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jac\/dkad070","article-title":"Efficacy of ceftazidime\/avibactam in various combinations for the treatment of experimental osteomyelitis in rabbits caused by OXA-48-\/ESBL-producing Escherichia coli","volume":"78","author":"Davido","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106702","article-title":"Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae","volume":"61","author":"Davido","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.06.015_bib49","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1128\/AAC.01718-12","article-title":"Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-\u03b2-lactamase-producing Escherichia coli in a foreign-body infection model","volume":"57","author":"Corvec","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.06.015_bib51","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/jac\/dkae111","article-title":"Population pharmacokinetic\/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections","volume":"79","author":"Wangchinda","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib52","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/jac\/dkac142","article-title":"Activity of fosfomycin\/colistin combinations against planktonic and biofilm Gram-negative pathogens","volume":"77","author":"Boncompagni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14787210.2021.1932463","article-title":"Intravenous fosfomycin for the treatment of patients with bone and joint infections: A review","volume":"20","author":"Tsegka","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2025.06.015_bib55","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3947\/ic.2016.48.4.324","article-title":"Acinetobacter prosthetic joint infection treated with debridement and high-dose tigecycline","volume":"48","author":"Vila","year":"2016","journal-title":"Infect Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib56","first-page":"2573","article-title":"Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: A unique challenge in the era of untreatable infections","author":"de Sanctis","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.015_bib57","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00344-24","article-title":"Zidovudine in synergistic combination with nitrofurantoin or omadacycline: In vitro and in murine urinary tract or lung infection evaluation against multidrug-resistant Klebsiella pneumoniae","volume":"68","author":"Tian","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib58","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1128\/AAC.04967-14","article-title":"Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli","volume":"59","author":"Grossman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib59","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa2020198","article-title":"Antibiotic Therapy for 6 or 12 weeks for prosthetic joint infection","volume":"384","author":"Bernard","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.015_bib60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eimc.2016.08.012","article-title":"Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)","volume":"35","author":"Ariza","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.cmi.2025.06.015_bib61","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jor.24906","article-title":"Facing multidrug-resistant pathogens in periprosthetic joint infections with self-administered outpatient parenteral antimicrobial therapy\u2014A prospective cohort study","volume":"39","author":"Frieler","year":"2021","journal-title":"J Orthop Res"},{"key":"10.1016\/j.cmi.2025.06.015_bib62","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/jac\/dkae177","article-title":"Current practices and challenges of outpatient parenteral antimicrobial therapy: A narrative review","volume":"79","author":"Wolie","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib63","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cmi.2019.09.007","article-title":"Suppressive antibiotic therapy in prosthetic joint infections: A multicentre cohort study","volume":"26","author":"Escudero-Sanchez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.06.015_bib64","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/jac\/dkz104","article-title":"Subcutaneous suppressive antibiotic therapy for bone and joint infections: Safety and outcome in a cohort of 10 patients","volume":"74","author":"Pouderoux","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib65","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1007\/s00402-024-05341-2","article-title":"Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: A systematic review","volume":"144","author":"Bruyninckx","year":"2024","journal-title":"Arch Orthop Trauma Surg"},{"key":"10.1016\/j.cmi.2025.06.015_bib66","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1093\/cid\/ciad533","article-title":"Phage therapy as a novel therapeutic for the treatment of bone and joint infections","volume":"77","author":"Suh","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.015_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106200","article-title":"Bacteriophage-antibiotic combinations against ciprofloxacin\/ceftriaxone-resistant Escherichia coli in vitro and in an experimental Galleria mellonella model","volume":"56","author":"Wang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.06.015_bib68","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/cid\/ciz222","article-title":"Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination","volume":"69","author":"Nir-Paz","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.015_bib69","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00924-19","article-title":"Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa","volume":"64","author":"Tkhilaishvili","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.015_bib70","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/antibiotics9020074","article-title":"Gram-negative bacterial lysins","volume":"9","author":"Ghose","year":"2020","journal-title":"Antibiotics (Basel)"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25003027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25003027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:23:12Z","timestamp":1788225792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25003027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1198743X25003027"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.06.015","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and strategies in the treatment of periprosthetic joint infection caused by multidrug-resistant Gram-negative bacteria: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}